… For patients treated with nirmatrelvir–ritonavir, we selected the first emergency department
… day after the nirmatrelvir–ritonavir order date, given that nirmatrelvir–ritonavir treatment was …

… 84% for Nirmatrelvir/Ritonavir against 100% for Molnupiravir. Only two patients died of
COVID-… significantly higher in patients treated with both antivirals—Nirmatrelvir/Ritonavir (aHR = …

… nirmatrelvir–ritonavir in patients with COVID-19 during a community epidemic in Hong Kong
dominated by the omicron … now indicated for non-hospitalised patients with COVID-19 who …

… of Omicron. Although in vitro data suggests that activity of nirmatrelvir against Omicron is
identical to previous variants, 15 data on clinical efficacy in patients infected with Omicron …

… effectiveness and safety of nirmatrelvir/ritonavir in hospitalized patients with severe
comorbidities and the Omicron variant of SARS-CoV-2. Consisting of 264 patients, it found no …

… and Omicron variants. However, data are limited concerning nirmatrelvir/ritonavir’s effectiveness
on subsequent Omicron … of nirmatrelvir/ritonavir therapy in patients with Omicron variant …

… We identified patients with COVID-19 who received either … nirmatrelvir plus ritonavir (nirmatrelvir
300 mg and ritonavir 100 mg twice daily for 5 days, or nirmatrelvir 150 mg and ritonavir …

… Among patients hospitalized with COVID-19 during the omicron wave in … patients
receiving nirmatrelvir-ritonavir and azvudine. However, it is worth noticing that nirmatrelvir-ritonavir …

… for high-risk patients with COVID-19. In trials amongst unvaccinated patients, nirmatrelvir/ritonavir …
Since then, emergence of the milder Omicron variant and improved immune protection …

… among patients who are high risk, 11 mainly in patients aged >65 … Omicron wave. This
study aims to retrospectively evaluate the effectiveness of nirmatrelvir + ritonavir among patients …